Author

Taylor Aurelius

Observed name: Aurelius, Taylor

Institutions: Drug Safety Research Unit, University of Portsmouth

Observed institutions: Royal Holloway University of London, Drug Safety Research Unit, University of Portsmouth

ORCID: 0000-0001-5925-1910

Observed ORCID: 0000-0001-5925-1910

OpenAlex ID: A5117415895

Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study

2025 · Sharifa Nasreen, Yannan Jiang, et al. · Vaccine · 16

Ischaemic stroke in South Asians: The BRAINS study

2022 · Taylor Aurelius, Ankita Maheshwari, et al. · European Journal of Neurology · 12

PDF

Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study

2025 · Alison Evans, Debabrata Roy, et al. · BMJ Open · 4

Diabetes mellitus and obesity among South Asians with ischemic stroke across three countries

2023 · Gie Ken-Dror, Intisar Ajami, et al. · International Journal of Stroke · 3

PDF

Atrial fibrillation in UK South Asian hospitalized ischemic stroke patients: The BRAINS study

2023 · Taylor Aurelius, Gie Ken-Dror, et al. · PLoS ONE · 3

PDF

A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements

2026 · Dawn Cooper, Mohammed Toseef Ansari, et al. · Drug Safety · 2

Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study

2026 · Joan Forns, Romin Pajouheshnia, et al. · Vaccine · 1

Validation of Guillain-Barré syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria

2026 · Mònica Sabaté, Judit Riera-Arnau, et al. · Vaccine · 1

Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group

2026 · Florence van Hunsel, Samantha Lane, et al. · Drug Safety · 1

PDF

TARGET-EU: Effectiveness of BNT162b2 mRNA COVID-19 vaccine in healthy individuals or with stable pre-existing medical conditions against SARS-CoV-2 infection

2026 · Andaur Navarro, Constanza L., Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)

TARGET-EU: Dapagliflozin and major adverse cardiovascular events in type 2 diabetes

2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)

TARGET-EU: Comparison of single-device vilanterol/fluticasone furoate with other single-device inhaled corticosteroid and long-acting beta agonist combinations in the risk of pneumonia in adolescents with asthma

2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)

TARGET-EU: The risk of angiooedema and other safety events in heart failure patients treated with sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors

2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)

DrugSet: A validated R Shiny application for reproducible drug codelist construction from ATC classification to CPRD Aurum prodcodes

2026 · Vjola Hoxhaj, Catherine Fry, et al. · medRxiv

PDF

TARGET-EU: Tolvaptan and risk associated to hepatotoxicity in autosomal dominant polycystic kidney disease

2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)

Harmonizing Case Validation for Vaccine Safety in Real-World Data: The VAC4EU Experience

2026 · Amirreza Dehghan Tarazjani, Daniel Weibel, et al. · Clinical Epidemiology

PDF

Works count: 16

Citation count: 43

H-index: 3

I10-index: 2